We are live on
!
Find out more
PAP
Persistent Asset Partners Portfolio holdings
AUM
$268M
1-Year Est. Return
158.98%
This Fund
S&P 500
This Quarter
Est. Return
+39.3%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$223M
AUM Growth
+$77.2M
(+53%)
Cap. Flow
+$48M
Cap. Flow
% of AUM
21.55%
Top 10 Holdings %
Top 10 Hldgs %
25.3%
Holding
464
New
223
Increased
67
Reduced
60
Closed
103
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Molina Healthcare
MOH
|
+$8.43M |
| 2 |
Elevance Health
ELV
|
+$5.15M |
| 3 |
Intel
INTC
|
+$4.26M |
| 4 |
SNDK
Sandisk
SNDK
|
+$3.61M |
| 5 |
Johnson & Johnson
JNJ
|
+$3.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$4.82M |
| 2 |
UnitedHealth
UNH
|
+$3.15M |
| 3 |
iShares Bitcoin Trust
IBIT
|
+$2.87M |
| 4 |
Regeneron Pharmaceuticals
REGN
|
+$2.84M |
| 5 |
Labcorp
LH
|
+$2.58M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 52.36% |
| 2 | Technology | 13.57% |
| 3 | Financials | 11.27% |
| 4 | Communication Services | 4.48% |
| 5 | Energy | 3.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Viridian Therapeutics
VRDN
$2.04B
| $176K | 0.08% |
+5,670
| New | +$156K |
|
227
Fair Isaac
FICO
$28.8B
| $176K | 0.08% |
+104
| New | +$179K |
|
228
Trip.com Group
TCOM
$27.8B
| $175K | 0.08% |
+2,434
| New | +$174K |
|
229
Affirm
AFRM
$25.5B
| $174K | 0.08% |
+2,339
| New | +$168K |
|
230
Rezolute
RZLT
$446M
| $171K | 0.08% |
+72,641
| New | +$569K |
|
231
Invivyd
IVVD
$220M
| $170K | 0.08% |
+68,843
| New | +$143K |
|
232
Structure Therapeutics
GPCR
$3.46B
| $169K | 0.08% |
+2,436
| New | +$99.5K |
|
233
CALL
Annexon
ANNX
$955M
| $168K | 0.08% |
+828
| New | +$3.17K |
|
234
Immix Biopharma
IMMX
$703M
| $166K | 0.07% |
+31,755
| New | +$131K |
|
235
Indivior Pharmaceuticals
INDV
$4.81B
| $163K | 0.07% |
4,530
-53,879
| -92% | -$1.65M |
|
236
Live Oak Bancshares
LOB
$1.97B
| $161K | 0.07% |
4,676
-18,051
| -79% | -$604K |
|
237
ArriVent BioPharma
AVBP
$1.56B
| $160K | 0.07% |
+7,963
| New | +$166K |
|
238
Lexeo Therapeutics
LXEO
$375M
| $159K | 0.07% |
+16,025
| New | +$146K |
|
|
239
CALL
Indivior Pharmaceuticals
INDV
$4.81B
| $159K | 0.07% |
+587
| New | +$17.9K |
|
|
CTNM
240
Contineum Therapeutics
CTNM
$549M
| $158K | 0.07% |
+13,853
| New | +$158K |
|
241
GE HealthCare
GEHC
$28.6B
| $157K | 0.07% |
+1,912
| New | +$149K |
|
242
Rhythm Pharmaceuticals
RYTM
$7.34B
| $155K | 0.07% |
+1,446
| New | +$153K |
|
|
HUYA
243
Huya Inc
HUYA
$556M
| $154K | 0.07% |
+53,305
| New | +$156K |
|
244
Ligand Pharmaceuticals
LGND
$6.11B
| $150K | 0.07% |
+791
| New | +$152K |
|
245
Stoke Therapeutics
STOK
$1.79B
| $145K | 0.07% |
+4,576
| New | +$138K |
|
246
Equillium
EQ
$166M
| $144K | 0.06% |
93,123
+24,132
| +35% | +$29.4K |
|
247
Chemed
CHE
$6.72B
| $144K | 0.06% |
+337
| New | +$147K |
|
248
Disc Medicine
IRON
$2.94B
| $141K | 0.06% |
+1,780
| New | +$150K |
|
249
Vor Biopharma
VOR
$995M
| $141K | 0.06% |
+10,798
| New | +$201K |
|
250
NewAmsterdam Pharma
NAMS
$3.69B
| $138K | 0.06% |
+3,948
| New | +$144K |
|
Similar funds
VC
AL
FC
NF
PF
UI
SSWM
AC
Persistent Asset Partners's Q4 2025 Portfolio in Review
As of Q4 2025, Persistent Asset Partners held 464 positions worth $223M, up 53% from $145M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Persistent Asset Partners deployed $48M of net new capital in Q4 2025, opening 223 new positions and adding to 67 existing holdings. Its largest new stake was Molina Healthcare: 51,285 shares worth $8.9M.
By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 49% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was UnitedHealth, an estimated $3.15M trimmed.
- Persistent Asset Partners's largest Q4 2025 buy was Molina Healthcare: 51,285 shares worth $8.9M.
- Persistent Asset Partners added most to Elevance Health in Q4 2025, an estimated $5.15M increase.
- Persistent Asset Partners's biggest Q4 2025 reduction was UnitedHealth, cutting an estimated $3.15M.
- Persistent Asset Partners fully exited iShares 7-10 Year Treasury Bond ETF in Q4 2025, selling an estimated $4.82M.
- Persistent Asset Partners's ten largest holdings make up 25% of its $223M portfolio in Q4 2025.
- Persistent Asset Partners opened 223 new positions and closed 103 in Q4 2025.
- Persistent Asset Partners's portfolio value rose 53% quarter-over-quarter to $223M.
Based on Persistent Asset Partners's 13F filing for Q4 2025, filed 17 Feb 2026.